���重受体激动剂的分子设计 — Beginner to Advanced

By Editorial Desk · published 2026-01-17 · last reviewed 2026-03-11 · Topic

If you have been reading about triple agonist and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Last reviewed on 2026-03-11. Where a claim depends on a specific study, the study is described rather than over-claimed.

三重受体激动剂的分子设计

该化合物处于临床试验阶段，尚未在多数地区取得上市许可。公开信息主要来自企业公告、学术会议摘要与试验注册平台记录，完整数据仍在逐步披露。关于长期疗效与安全性的判断，需要等待规模更大、随访更久的研究结果，目前不宜对最终结论作出预判。

retatrutide 是一种人工合成的多肽，设计目标是同时作用于 GIP、GLP-1 与胰高血糖素三种受体。这种三重激动设计试图把多条代谢通路的调节整合进单一分子，而不是只依赖一种肠促胰素受体。分子骨架以天然肽序列为基础，经过非天然氨基酸替换和脂肪酸侧链修饰，以获得更长的作用时间。该方向属于多受体激动剂研究的一部分，与双重激动剂的工作并行推进。

三种受体在能量平衡中的分工并不相同：GLP-1 与 GIP 受体主要参与胰岛素分泌和食欲调节，胰高血糖素受体则与能量消耗及肝糖输出相关。同时激活三者可能产生叠加效应，也可能出现相互制约，具体结果取决于受体亲和力与组织分布。这种组合在理论上可能同时影响体重与血糖指标，但协同关系的细节仍处在研究阶段。

Molecular Identity and Receptor Targets

Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.

Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.

Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.

Retatrutide at a glance

瑞他鲁肽药理机制

瑞他鲁肽同时激活GLP-1受体、GIP受体和胰高血糖素受体，这三者均属于B类G蛋白偶联受体。受体激活后主要经cAMP信号通路传递效应。GLP-1成分与食欲抑制和胃排空延缓相关，GIP成分影响脂肪组织与胰岛素分泌，胰高血糖素成分则促进肝糖输出和能量消耗。各受体贡献的相对比例在人体中尚未完全量化。

该分子是经过结构修饰的合成肽，通过脂肪酸侧链与白蛋白结合，从而延长循环时间。皮下给药后，药物逐步释放并分布至组织。降解主要依赖蛋白酶，肾脏清除占次要地位。人体半衰期以天为单位，但准确数值随检测方法和个体差异而变；组织分布与受体占有率仍是开放问题。

临床研究通常测量体重、腰围、空腹血糖、糖化血红蛋白和血脂，并记录不良事件。药代动力学评估关注浓度-时间曲线，药效动力学评估关注代谢标志物变化。体重下降由能量摄入减少、能量消耗变化和脂肪组织重塑共同造成，具体权重仍不明确。研究之间的终点定义和随访时长差异使横向比较复杂。

Related pages on this site

• Scheduled toolkit
• Tracked digest
• Simple index
• Seasonal casebook
• Regional briefing
• Professional reference
• Connected archive
• Smart toolkit

Discovery and Triple Receptor Pharmacology

Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.

Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.

Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.

Notes from published material

Increasingly restrictive drug laws of the 1960s and the 1970s curbed scientific research into the effects of psilocybin and other hallucinogens, but its popularity as an entheogen grew in the next decade, owing largely to the increased availability of information on how to cultivate psilocybin mushrooms. Possession of psilocybin-containing mushrooms has been outlawed in most countries, and psilocybin is classified as a Schedule I controlled substance in the 1971 United Nations Convention on Psychotropic Substances. Psilocybin is being studied as a possible medicine in the treatment of psychiatric disorders such as major depressive disorder, substance use disorders, obsessive–compulsive disorder, and other conditions such as cluster headaches. Psilocybin was approved for treatment-resistant depression in Australia in 2023. It is in late-stage clinical trials in the United States for major depressive disorder and treatment-resistant depression. As of September 2026, complete submission of psilocybin for treatment-resistant depression is expected in the fourth quarter of 2026 and commercial launch for this indication is anticipated in the first half of 2027. Especially at higher doses and combined with psychological support, single doses of psilocybin may produce rapid and long-lasting antidepressant effects that outperform placebo, though they may produce either modest or no effectiveness advantage over continuous use of selective serotonin reuptake inhibitors (SSRIs) like escitalopram and trial methodological issues are common.

=== Oxygen and small molecule dependent degrons === The presence of oxygen or other small molecules can influence degron recognition. The von Hippel-Lindau (VHL) protein (substrate recognition part of a specific E3 ligase), for instance, recognizes the hypoxia-inducible factor alpha (HIF-α) only under normal oxygen conditions, when its proline is hydroxylated. Under hypoxia, on the other hand, HIF-a is not hydroxylated, evades ubiquitination and thus operates in the cell at higher concentrations which can initiate transcriptional response to hypoxia. Another example of small molecule control of protein degradation is phytohormone auxin in plants. Auxin binds to TIR1 (the substrate recognition domain of SCFTIR1ubiquitin ligase) increasing the affinity of TIR1 for its substrates (transcriptional repressors: Aux/IAA), and promoting their degradation.

==== Estimating uncertainty ==== It is often important for human operators to gauge how much they should trust an AI system, especially in high-stakes settings such as medical diagnosis. ML models generally express confidence by outputting probabilities; however, they are often overconfident, especially in situations that differ from those that they were trained to handle. Calibration research aims to make model probabilities correspond as closely as possible to the true proportion that the model is correct. Similarly, anomaly detection or out-of-distribution (OOD) detection aims to identify when an AI system is in an unusual situation. For example, if a sensor on an autonomous vehicle is malfunctioning, or it encounters challenging terrain, it should alert the driver to take control or pull over. Anomaly detection has been implemented by simply training a classifier to distinguish anomalous and non-anomalous inputs, though a range of additional techniques are in use.

Aromas can be formed via amino acid decomposition, Maillard reaction, sugar cyclization, and lipid oxidation. A complex mix of aromas similar to butter, meat, bone stock, wood smoke, lovage and many other substances can be produced, depending on reaction conditions (time, temperature, hydrolysis method, additional feedstock such as xylose and spices). According to the European Code of Practice for Bouillons and Consommés, hydrolyzed protein products intended for retail sale correspond to these characteristics:

Sources: en.wikipedia.org

Further detail

In addition, they claim that the Matazetas are "prohibited to extort, kidnap, steal, abuse, or do anything that will affect the national patrimony", and that they are the "armed wing of the Mexican people." On 6 October 2011 in Boca del Río, Veracruz, 36 bodies were found by the Mexican authorities in three different houses. The Navy first discovered 20 bodies inside a house in a residential neighborhood. While searching at another house they found 11 more bodies. The third and final house contained one body. Four other bodies were confirmed separately by the state government of Veracruz. A day later, Reynaldo Escobar Pérez, the State Justice Attorney General, stepped down and resigned due to the drug-violence. And a day after his resignation, 10 more bodies were found throughout the city of Veracruz. The CJNG was also responsible for 67 killings in Veracruz on 7 October 2011. By 9 October 2011, in only eighteen days, the state of Veracruz reported 100 killings.

=== Functional Genomics === This program studies genes involved in physiological systems and their pharmaceutical applications. It characterizes gene functions and interactions using rodent models at the Czech Centre for Phenogenomics, which is part of the Infrafrontier consortium. Research includes liver function, cardiovascular dysfunction, diabetes, metabolic disorders, hearing loss, and ocular disease.

== Route alignment == The Mumbai–Nagpur Expressway will travel through 10 key districts directly and 14 districts indirectly via feeder roads, 24 talukas, and 392 villages. The 10 main districts are Nagpur, Wardha, Amravati, Washim, Buldhana, Jalna, Aurangabad, Nashik, Ahmednagar, and Thane. The other 14 districts include Chandrapur, Bhandara, Gondia, Gadchiroli, Yavatmal, Akola, Hingoli, Parbhani, Nanded, Beed, Dhule, Jalgaon, Palghar, and Raigad. Yavatmal City is going to connect with Four Lane road to the Samruddhi Expressway and Amravati too. Four Lane Road will be constructed between Yavatmal City and Badnera.

Sources: en.wikipedia.org

Frequently asked questions